Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.43 |
| ▸ | PDE2A | O00408 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | TDO2 | P48775 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29528356 | 1.00 | CES2 (0.50) | CES2CES1CYP3A4CYP2D6SLC6A2 | |
| SCHEMBL252143 | 1.00 | CES2 (0.50) | CES2CES1CYP3A4CYP2D6SLC6A2 | |
| SCHEMBL252144 | 1.00 | CES2 (0.50) | CES2CES1CYP3A4CYP2D6SLC6A2 | |
| SCHEMBL253183 | 1.00 | CES2 (0.50) | CES2CES1CYP3A4CYP2D6SLC6A2 | |
| SCHEMBL253771 | 1.00 | CES2 (0.50) | CES2CES1CYP3A4CYP2D6SLC6A2 | |
| SCHEMBL29528216 | 1.00 | CES2 (0.50) | CES2CES1CYP3A4CYP2D6SLC6A2 | |
| SCHEMBL9667214 | 0.88 | PDE2A (0.50) | CES2CES1CYP3A4CYP2D6SLC6A2 | |
| SCHEMBL11602791 | 0.88 | CES2 (0.54) | CES2CES1CYP3A4CYP2D6SLC6A2 | |
| SCHEMBL5684729 | 0.82 | CES2 (0.46) | CES2CES1CYP3A4CYP2D6SLC6A2 | |
| SCHEMBL625219 | 0.81 | CES2 (0.48) | CES2CES1CYP3A4CYP2D6SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3423433-B1 | SULFAMATE DERIVATIVE COMPOUNDS, PROCESSES FOR PREPARING THEM AND THEIR USES | BIO PHARM SOLUTIONS CO LTD (KR) | 2025-12-17 | — | — | EP | disclosed |
| EP-2970112-B1 | PHENYL CARBAMATE COMPOUND AND A COMPOSITION FOR PREVENTING OR TREATING A MEMORY LOSS-RELATED DISEASE COMPRISING THE SAME | BIO PHARM SOLUTIONS CO LTD (KR) | 2025-03-12 | — | — | EP | disclosed |
| EP-2968210-B1 | PHENYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING PEDIATRIC EPILESY | BIO PHARM SOLUTIONS CO LTD (KR) | 2024-09-11 | — | — | EP | disclosed |
| US-11931332-B2 | Phenyl alkyl carbamate compounds for use in preventing or treating neurodegenerative disease | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2024-03-19 | — | — | US | disclosed |
| EP-4204395-A1 | PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING NEURODEGENERATIVE DISEASE | Bio-Pharm Solutions Co., Ltd. (KR) | 2023-07-05 | — | — | EP | disclosed |
| EP-2968211-B1 | PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME | BIO PHARM SOLUTIONS CO LTD (KR) | 2021-05-12 | — | — | EP | disclosed |
| EP-2968211-B1 | PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME | BIO PHARM SOLUTIONS CO LTD (KR) | 2021-05-12 | — | — | EP | disclosed |
| US-10525030-B2 | Phenyl carbamate compound and a composition for neuroprotection comprising the same | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2020-01-07 | — | — | US | disclosed |
| US-10525030-B2 | Phenyl carbamate compound and a composition for neuroprotection comprising the same | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2020-01-07 | — | — | US | disclosed |
| US-10351519-B2 | Sulfamate derivative compounds, processes for preparing them and their uses | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2019-07-16 | — | — | US | disclosed |
| US-20130005801-A1 | PHENYLCARBAMATE COMPOUND AND MUSCLE RELAXANT CONTAINING THE SAME | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2013-01-03 | — | — | US | disclosed |
| US-20130005801-A1 | PHENYLCARBAMATE COMPOUND AND MUSCLE RELAXANT CONTAINING THE SAME | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2013-01-03 | — | — | US | disclosed |
| US-20130005801-A1 | PHENYLCARBAMATE COMPOUND AND MUSCLE RELAXANT CONTAINING THE SAME | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2013-01-03 | — | — | US | disclosed |
| US-20120184762-A1 | PROCESS FOR PREPARATION OF PHENYL CARBAMATE DERIVATIVES | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2012-07-19 | — | — | US | disclosed |
| US-20120184762-A1 | PROCESS FOR PREPARATION OF PHENYL CARBAMATE DERIVATIVES | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2012-07-19 | — | — | US | disclosed |
| US-20120184762-A1 | PROCESS FOR PREPARATION OF PHENYL CARBAMATE DERIVATIVES | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2012-07-19 | — | — | US | disclosed |
| WO-2012096458-A2 | PROCESS FOR PREPARATION OF PHENYL CARBAMATE DERIVATIVES | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2012-07-19 | — | — | WO | disclosed |
| WO-2012096458-A2 | PROCESS FOR PREPARATION OF PHENYL CARBAMATE DERIVATIVES | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2012-07-19 | — | — | WO | disclosed |
| WO-2012002773-A2 | PHENYLCARBAMATE COMPOUND AND MUSCLE RELAXANT CONTAINING THE SAME | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2012-01-05 | — | — | WO | disclosed |
| WO-2012002773-A2 | PHENYLCARBAMATE COMPOUND AND MUSCLE RELAXANT CONTAINING THE SAME | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10351519-B2 | Sulfamate derivative compounds, processes for preparing them and their uses | STS, SULT2A1, SULT1A1 | CES2 607/4885CES1 1048/4885CYP3A4 1003/4885 |
| US-20130005801-A1 | PHENYLCARBAMATE COMPOUND AND MUSCLE RELAXANT CONTAINING THE SAME | CPT1B, MYLK, PYGM | CES2 1121/4885CES1 528/4885CYP3A4 211/4885 |
| US-10525030-B2 | Phenyl carbamate compound and a composition for neuroprotection comprising the same | CHAT, BAX, CASP3 | CES2 481/4885CES1 1183/4885CYP3A4 3847/4885 |
| US-11931332-B2 | Phenyl alkyl carbamate compounds for use in preventing or treating neurodegenerative disease | SNCA, MAPT, CHAT | CES2 1914/4885CES1 3832/4885CYP3A4 4695/4885 |
| US-20120184762-A1 | PROCESS FOR PREPARATION OF PHENYL CARBAMATE DERIVATIVES | CPS1, BCHE, ACHE | CES2 7/4885CES1 171/4885CYP3A4 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.